This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent. Top assignee: Celgene Quanticel Research, Inc.. Active years: 2020-2023.
Company Filing History:
Years Active: 2020-2023
Title: Ryan Stansfield: Innovator in Pharmaceutical Research
Introduction
Ryan Stansfield is a notable inventor based in San Diego, California. He has made significant contributions to the field of pharmaceutical research, particularly in the development of bromodomain inhibitors. With a total of two patents to his name, Stansfield's work is paving the way for advancements in cancer treatment.
Latest Patents
Stansfield's latest patents focus on the bromodomain inhibitor 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one. This invention includes various forms such as crystalline, amorphous, solvates, and hydrates. The pharmaceutical compositions that incorporate this bromodomain inhibitor are designed for the treatment of cancer or neoplastic diseases. The compositions may also include processed forms of the inhibitor, such as those that have been micronized or spray dried. Additionally, these compositions can comprise a solid polymer matrix, enhancing their effectiveness in medical applications.
Career Highlights
Ryan Stansfield is currently employed at Celgene Quanticel Research, Inc., where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to developing effective treatments for serious health conditions.
Collaborations
Stansfield collaborates with esteemed colleagues, including Jeffrey Alan Stafford and James Marvin Veal. Their combined expertise contributes to the advancement of research and development in their field.
Conclusion
Ryan Stansfield is a prominent figure in pharmaceutical innovation, particularly in the area of cancer treatment. His patents and ongoing research efforts are crucial for the future of medical therapies.